北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2025 年第一次临时股东大会的 法 律 意 见 书 康达(杭州)股会字【2025】第 0027 号 二〇二五年九月 北京康达（杭州）律师事务所 海正药业 2025 年第一次临时股东大会法律意见书 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正药业股份有限 公司（下称"海正药业"或"公司"）委托，指派本所律师出席公司 2025 年第 一次临时股东大会（下称"本次股东大会"）。根据《中华人民共和国公司法》 （下称"《公司法》"）、《中华人民共和国证券法》（下称"《证券法》"）、 《律师事 ...

证券代码：600267 证券简称：海正药业 公告编号：临2025-53号 浙江海正药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 10 日 (二)股东大会召开的地点：浙江海正药业股份有限公司会议室（台州市椒江区外 沙路 46 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 677 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 493,100,047 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 42.3940 | (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关于取消监事会并修订《公司章程》的议案 审议结果：通过 表决情况： 注：截至本次股东 ...

Investment Rating - The report maintains a "Buy" rating for the company based on its stable growth in traditional businesses and accelerated new business development [4][9]. Core Insights - In the first half of 2025, the company achieved a revenue of 5.25 billion yuan, a slight increase of 0.13%, while the net profit attributable to shareholders was 299 million yuan, a decrease of 31.29%. The non-recurring net profit improved significantly to 321 million yuan, reflecting a growth of 23.92% [1][4]. - The operating cash flow showed a substantial improvement, reaching 1.211 billion yuan, an increase of 54.98%. The gross margin was 43.94%, up by 4.57 percentage points, while the net margin decreased to 5.81%, down by 2.47 percentage points [1][4]. - The company has optimized its sales system, with a significant increase in its formulation business, achieving over 30% growth in sales revenue in the first half of 2025. The core product, Haibomai Tablets, also saw a sales growth exceeding 30% [1][2]. Financial Performance Summary - Revenue projections for 2025-2027 are estimated at 11.728 billion yuan, 13.039 billion yuan, and 14.383 billion yuan, representing year-on-year growth rates of 13.4%, 11.2%, and 10.3% respectively [2][8]. - The net profit attributable to shareholders is forecasted to be 707 million yuan, 842 million yuan, and 994 million yuan for the same period, with growth rates of 17.6%, 19.0%, and 18.1% respectively [2][8]. - The earnings per share (EPS) is expected to increase from 0.59 yuan in 2025 to 0.83 yuan in 2027, with a corresponding decrease in the price-to-earnings (P/E) ratio from 18.0 to 12.8 [2][8].

Industry Overview - The 27th Asia Pet Expo attracted over 510,000 visitors, showcasing the robust growth of China's pet economy, with a market size projected to reach 811.4 billion yuan by 2025, growing at a compound annual growth rate (CAGR) of 25.4% from 2015 to 2023 [1] - The pet-related business market in China has expanded from 97.8 billion yuan in 2015 to 592.8 billion yuan in 2023, indicating a significant upward trend [1] Company Performance - The pet sector achieved revenue of 6.381 billion yuan in the first half of 2025, a year-on-year increase of 22.03%, with net profit reaching 660 million yuan, up 20.28% [1] - Leading company Guobao Pet reported revenue of 3.221 billion yuan and net profit of 378 million yuan, with growth rates of 32.72% and 22.55% respectively [2] - Zhongchong Co. followed closely with revenue of 2.432 billion yuan and net profit of 203 million yuan, marking a 42.56% increase in net profit, the highest in the industry [2] - Petty Co. experienced a decline in both revenue and net profit, reporting 728 million yuan and 79 million yuan, down 13.94% and 19.23% respectively, attributed to U.S. tariff policies affecting overseas orders [3] - Lusi Co. reported an 11.32% increase in revenue to 391 million yuan but a 12.07% decrease in net profit to 30.46 million yuan due to falling product prices [3] Market Trends - The pet economy is driven by a generational shift in consumer attitudes, with younger generations (90s and 00s) becoming the primary pet owners, leading to a growing "it economy" around pets [5] - The pet food market holds a 52.8% share, followed by pet medical services at 28.0%, with increasing penetration rates in pet diagnosis, training, insurance, and travel [5] - The average cost of pet medical services is rising due to advancements in medical technology and diversified drug supply [5] Regulatory Environment - Recent policies from the Ministry of Agriculture and Rural Affairs and the State Administration for Market Regulation have focused on establishing standards for the pet industry [6] - Local governments are incorporating pet industry development into their plans, with initiatives aimed at promoting collaboration across various sectors [6] Investment Activity - The pet industry has seen 634 financing events as of the first quarter of 2025, with online platforms being the most active [6] - The pet economy concept index has risen by 43.21% year-to-date, indicating strong interest from the capital market [7]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. is convening its first extraordinary general meeting of shareholders in 2025 on September 10, 2025, utilizing both on-site and online voting methods [1][2]. Meeting Basic Information - The meeting type is the first extraordinary general meeting of shareholders in 2025 [1]. - The meeting is convened by the Board of Directors following the sixth meeting of the tenth Board [1]. - Voting will be conducted through a combination of on-site and online methods [1]. - The on-site meeting will take place at the company's conference room in Taizhou, Zhejiang Province, starting at 14:00 on September 10, 2025 [1]. - Online voting will be available on the Shanghai Stock Exchange's shareholder meeting voting system from 9:15 to 15:00 on the same day [1]. Voting Procedures - Shareholders involved in margin trading, transfer, and other related accounts must follow the relevant regulations for voting [2]. - The meeting will review proposals that have been disclosed in advance through various media [3]. - There are no separate votes for minority investors or related shareholders [4]. Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited after the close of trading on the registration date are eligible to attend [7]. - Registration for attendance can be done in person or through written authorization for representatives [9]. - Registration will occur on September 8, 2025, at the company's securities department [11]. Additional Information - The meeting will last half a day, and attendees are responsible for their own travel and accommodation [13]. - The company will provide a reminder service for shareholders to ensure participation in the voting process [13]. - Contact information for the company is provided for further inquiries [14].

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. is set to hold its first extraordinary general meeting of shareholders in 2025 on September 10, 2025, utilizing both on-site and online voting methods [2][3]. Meeting Details - The meeting will take place on September 10, 2025, at 14:00 in the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [3][9]. - The voting will be conducted through the Shanghai Stock Exchange's online voting system, with specific time slots for trading system voting and internet voting [3][4]. Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system, either through a designated trading terminal or the internet voting platform [6][7]. - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same category of shares [7][8]. Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the close of trading on the registration date are eligible to attend the meeting [9]. - Registration for attendance can be done in person or via mail/fax, with specific registration times set for September 8, 2025 [12][13]. Additional Information - The company aims to enhance participation from small and medium investors by providing reminder services through SMS notifications about the meeting and voting [14]. - The meeting will last for half a day, and attendees are responsible for their own travel and accommodation [14].

Core Points - The Zhejiang Haizheng Pharmaceutical Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 on September 10, 2025, to discuss key proposals [1][2] - The agenda includes the revision of the remuneration management system for directors and senior management, the cancellation of the supervisory board, and amendments to the company's articles of association [3][4] Meeting Agenda - The meeting will start with the announcement of the qualification review results of attending representatives [1] - Proposals to be reviewed include the revision of the remuneration management system for directors and senior management, which has already been approved by the board [1][3] - Shareholders and their authorized representatives will have the opportunity to speak and ask questions [1] - Voting will be conducted on the proposals, followed by the counting of valid votes [1][2] - The results of the voting will be announced, and the resolutions of the shareholders' meeting will be read [1][2] Proposal Details - Proposal 1 involves the cancellation of the supervisory board and amendments to the company's articles of association, with the supervisory board's responsibilities being transferred to the audit committee of the board [3][4] - Proposal 2 focuses on the formulation, revision, and abolition of certain corporate governance systems to enhance the company's operational standards and governance structure [4]

证券日报网讯9月3日晚间，海正药业（600267）发布公告称，公司将于2025年9月10日召开2025年第一 次临时股东大会。本次股东大会将审议《关于取消监事会并修订 <公司章程> 的议案》《关于制定、修 订、废止部分公司治理制度的议案》等多项议案。 ...

Market Performance - The Artemisinin concept index rose by 0.17%, ranking third among concept sectors, with three stocks increasing in value, including Baihua Medicine which hit the daily limit, and Fosun Pharma and China Resources Sanjiu which rose by 0.39% and 0.05% respectively [1] - The top gainers in the Artemisinin sector were Baihua Medicine, Fosun Pharma, and China Resources Sanjiu, while the biggest losers included Delong Huineng, New Harmony, and Zhejiang Medicine, which fell by 3.33%, 1.18%, and 1.17% respectively [1] Capital Flow - The Artemisinin concept sector experienced a net outflow of 58 million yuan in main capital, with Baihua Medicine receiving the highest net inflow of 109 million yuan, followed by China Resources Sanjiu and Zhejiang Medicine with net inflows of 14.16 million yuan and 5.79 million yuan respectively [2] - The net inflow ratios for Baihua Medicine, China Resources Sanjiu, and Zhejiang Medicine were 29.47%, 5.98%, and 2.65% respectively, indicating strong interest in these stocks [3] Stock Performance Details - Baihua Medicine had a daily increase of 10.03% with a turnover rate of 9.48% and a main capital flow of 108.91 million yuan, leading the sector [3] - Other notable stocks included China Resources Sanjiu with a slight increase of 0.05% and a turnover rate of 1.18%, and Zhejiang Medicine which decreased by 1.17% with a turnover rate of 1.48% [3][4]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 10, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The on-site meeting will take place at the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [1][6] Voting Procedures - Online voting will be conducted through the Shanghai Stock Exchange's shareholder meeting online voting system, available from 9:15 AM to 3:00 PM on the day of the meeting [2][4] - Shareholders can vote via the trading system during specific trading hours [2] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [4] Agenda Items - The meeting will review several proposals, including amendments to the company's management systems and governance rules [3][7] - The proposal to revise the remuneration management system for directors and senior management has already been approved by the board [3] Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the close of trading on September 4, 2025, are eligible to attend [5] - Registration for attendance must be completed by September 8, 2025, with specific documentation required [5][6] Additional Services - The company will provide a reminder service for shareholders to ensure participation in the meeting through SMS notifications [6]